Literature DB >> 16368586

Prevalence and correlates of depression in treatment-seeking women with vulvodynia.

R M Masheb1, E Wang, C Lozano, R D Kerns.   

Abstract

This study aimed to examine rates and correlates of depression in a treatment-seeking sample of women with vulvodynia. A total of 53 women were independently diagnosed with vulvodynia and assessed with state-of-the-art measures of major depressive disorder (MDD) and depressive symptom severity as well as psychometrically established measures of pain severity, general functioning, sexual function and quality of life. Current and lifetime prevalence rates for MDD were 17% (n = 9) and 45% (n = 24), respectively. Women with current MDD reported significantly greater pain severity, and worse functioning and quality of life than women without current MDD. Among those with lifetime MDD, the majority (62.5%) reported that their first depressive episode occurred before the onset of vulvodynia. Rates of current MDD appeared to be lower than rates of MDD among other samples of treatment seeking chronic pain patients. In summary, co-morbid MDD is related to greater pain severity and worse functioning among women with vulvodynia.

Entities:  

Mesh:

Year:  2005        PMID: 16368586     DOI: 10.1080/01443610500328199

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  10 in total

Review 1.  [Review of the literature on the psychoemotional reality of women with vulvodynia: difficulties met and strategies developed].

Authors:  M Cantin-Drouin; D Damant; D Turcotte
Journal:  Pain Res Manag       Date:  2008 May-Jun       Impact factor: 3.037

2.  Psychosexual correlates of persistent postsurgical pain in patients with vulvodynia.

Authors:  Alisa Eanes; Eric Bair; Caitlin Martin; Priya Iyer; Denniz Zolnoun
Journal:  Int J Gynaecol Obstet       Date:  2011-04-09       Impact factor: 3.561

3.  The influence of depression and anxiety on risk of adult onset vulvodynia.

Authors:  Maheruh Khandker; Sonya S Brady; Allison F Vitonis; Richard F Maclehose; Elizabeth G Stewart; Bernard L Harlow
Journal:  J Womens Health (Larchmt)       Date:  2011-08-08       Impact factor: 2.681

4.  Effects of vulvodynia on quality of life.

Authors:  Maya Ponte; Erika Klemperer; Anju Sahay; Mary-Margaret Chren
Journal:  J Am Acad Dermatol       Date:  2008-11-20       Impact factor: 11.527

5.  A randomized clinical trial for women with vulvodynia: Cognitive-behavioral therapy vs. supportive psychotherapy.

Authors:  Robin M Masheb; Robert D Kerns; Christine Lozano; Mary Jane Minkin; Susan Richman
Journal:  Pain       Date:  2008-11-20       Impact factor: 6.961

6.  Depression and posttraumatic stress disorder among women with vulvodynia: evidence from the population-based woman to woman health study.

Authors:  Lisbeth Iglesias-Rios; Siobán D Harlow; Barbara D Reed
Journal:  J Womens Health (Larchmt)       Date:  2015-05-07       Impact factor: 2.681

7.  Vulvodynia is not created equally: empirical classification of women with vulvodynia.

Authors:  Meryl Alappattu; Georgine Lamvu; Jessica Feranec; Kathryn Witzeman; Michael Robinson; Andrea Rapkin
Journal:  J Pain Res       Date:  2017-07-06       Impact factor: 3.133

8.  Exploring Pain-Related Anxiety and Depression in Female Patients With Provoked Vulvodynia With Associated Overactive Pelvic Floor Muscle Dysfunction.

Authors:  Vaishnavi Govind; Jill M Krapf; Leia Mitchell; Karissa Barela; Hillary Tolson; Jaqueline Casey; Andrew T Goldstein
Journal:  Sex Med       Date:  2020-06-24       Impact factor: 2.491

9.  An Investigation of Descending Pain Modulation in Women With Provoked Vestibulodynia: Alterations of Brain Connectivity.

Authors:  Lindsey R Yessick; Caroline F Pukall; Gabriela Ioachim; Susan M Chamberlain; Patrick W Stroman
Journal:  Front Pain Res (Lausanne)       Date:  2021-06-17

Review 10.  Vulvodynia: a consideration of clinical and methodological research challenges and recommended solutions.

Authors:  Serena Corsini-Munt; Kate M Rancourt; Justin P Dubé; Meghan A Rossi; Natalie O Rosen
Journal:  J Pain Res       Date:  2017-10-09       Impact factor: 3.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.